- Expertise article
- Zuckermann et al., 2008 (study 8)
Investigators – Zuckerman; Roof; Vaughn; Wes Johnson (BIVI – U. Illinois Collaboration)
The objective of this study was to evaluate several adjuvants and/or immunomodulators in combination with Ingelvac® PRRS MLV and investigate potential clinical or immunological improvements in vivo. The study evaluated Ingelvac® PRRS MLV vaccine (USDA licensed) alone and in combination with various potential immunostimulators including:
-
HS – adjuvant
-
ORF 5 Pool – A pool of peptides representing the ORF 5 ectodomain region of five different PRRS virus isolates.
-
INF alpha DNA vaccine provided by Dr. Zuckerman along with concurrent injections of purified and recombinant INF alpha from PBL Biomedical laboratories (100,000 units/dose).
• Poly ICLC (50 ug/kg) from Ribopharm, Inc. which has been reported to act as an interferon inducer and activates anti-viral immunity.
• IL-12 recombinant protein (2 ug/dose, 2 hours pre and post-vacc with MLV) from R&D Systems Inc. which has been shown to enhance T cell and NK cell activity.
Read the full publication here.